Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:27:59 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



News for U:SNY from 2025-02-07 to 2026-02-06 - 25 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2026-02-03 08:00U:SNYNews ReleaseRezurock(TM) now reimbursed in Ontario and British Columbia for people living with chronic graft-versus-host disease (GVHD)
2025-12-23 01:00U:SNYNews ReleaseDupixent(TM) (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
2025-11-25 01:00U:SNYNews ReleaseDupixent(TM) (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
2025-10-27 20:48U:SNYNews ReleaseUPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
2025-10-23 01:00U:SNYNews ReleaseSanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey
2025-10-21 13:52U:SNYNews Release/C O R R E C T I O N -- Sanofi-Aventis Canada Inc./
2025-10-16 06:00U:SNYNews ReleaseEVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi
2025-09-26 08:00U:SNYNews ReleaseSanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US
2025-09-22 00:29U:SNYNews ReleaseDupixent(TM) (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion
2025-09-10 08:00U:SNYNews ReleaseMandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS(TM)
2025-08-26 11:00U:SNYNews ReleaseNew Report Highlights Community Health Workers' Impact, Calls for Sustained Local Investment, During National CHW Awareness Week
2025-07-22 11:57U:SNYNews ReleaseBEYFORTUS(TM) reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study
2025-06-26 08:00U:SNYNews ReleaseSanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts
2025-06-15 11:21U:SNYNews ReleaseDupixent(TM) (dupilumab) Demonstrated Superiority Over Xolair(TM) (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
2025-06-02 01:25U:SNYNews ReleaseSanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
2025-05-30 01:00U:SNYNews ReleaseItepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
2025-05-22 17:30U:SNYNews ReleaseSanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence
2025-05-21 19:31U:SNYNews ReleaseVigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
2025-05-14 12:30U:SNYNews ReleaseSanofi to invest at least $20 billion in the US through 2030, growing investments in science and expanding domestic manufacturing
2025-04-18 11:16U:SNYNews ReleaseDupixent(TM) (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
2025-04-15 08:00U:SNYNews ReleaseChrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement
2025-03-28 02:00U:SNYNews ReleaseDupixent(TM) (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
2025-03-14 14:18U:SNYNews ReleaseSanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
2025-03-08 13:00U:SNYNews ReleaseDupixent(TM) (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
2025-02-22 02:20U:SNYNews ReleaseTeva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn's Disease